Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 51, 2017, Pages E10981-E10990

  Stone, Meredith L ^a,d   Chiappinelli, Katherine B ^a,e   Li, Huili ^a   Murphy, Lauren M ^a   Travers, Meghan E ^a   Topper, Michael J ^a   Mathios, Dimitrios ^a   Lim, Michael ^a   Shih, Ie Ming ^a   Wang, Tian Li ^a   Hung, Chien Fu ^a   Bhargava, Vipul ^b   Wiehagen, Karla R ^b   Cowley, Glenn S ^b   Bachman, Kurtis E ^b   Strick, Reiner ^c   Strissel, Pamela L ^c   Baylin, Stephen B ^a   Zahnow, Cynthia A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

5 azacytidine; Histone deacetylase inhibitors; Immunosuppression; Ovarian cancer; Type I interferon

Indexed keywords

ALPHA IFNAR1 PROTEIN; AZACITIDINE; CD45 ANTIGEN; ENTINOSTAT; GIVINOSTAT; INTERFERON; PROGRAMMED DEATH 1 RECEPTOR ALPHA INHIBITOR; PROTEIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; HISTONE DEACETYLASE INHIBITOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE THERAPY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MACROPHAGE; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NONHUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; GENETIC EPIGENESIS; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; AZACITIDINE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; FEMALE; HISTONE DEACETYLASE INHIBITORS; IMMUNOMODULATION; INTERFERON TYPE I; MICE; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85038809954     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1712514114     Document Type: Article

References (65)

1. Siegel RL, Miller KD, Jemal A. (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7-30.
2. Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson K.L. (2011) Immunity and immune suppression in human ovarian cancer. Immunotherapy 3:539-556.
3. Chester C, Dorigo O, Berek JS, Kohrt H. (2015) Immunotherapeutic approaches to ovarian cancer treatment. J Immunother Cancer 3:7.
4. Brahmer JR, et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465.
5. Juergens RA, et al (2011) Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 1:598-607.
6. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. (2012) Epigenetic protein families: A new frontier for drug discovery. Nat Rev Drug Discov 11:384-400.
7. Zahnow CA, et al (2016) Inhibitors of DNA methylation, histone deacetylation, and histone demethylation: A perfect combination for cancer therapy. Adv Cancer Res 130:55-111.
8. Allis CD, Caparros M-L, Jenuwein T, Reinberg D, Lachlan M. (2015) Epigenetics (Cold Spring Harbor Lab Press, Cold Spring Harbor, NY), 2nd Ed.
9. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107.
10. Wrangle J, et al (2013) Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4:2067-2079.
11. Chiappinelli KB, et al (2015) Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162:974-986, and errata (2016) 164:1073 and (2017) 169:361.
12. Matei D, et al (2012) Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 72:2197-2205.
13. Li H, et al (2014) Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5:587-598.
14. Roulois D, et al (2015) DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162:961-973.
15. Peng D, et al (2015) Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527:249-253.
16. Ghoneim HE, et al (2017) De novo epigenetic programs inhibit PD-1 blockademediated T cell rejuvenation. Cell 170:142-157.e19.
17. Topper et al., Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell, in press.
18. Conejo-Garcia JR, et al (2004) Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 10:950-958.
19. Hung CF, et al (2007) Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther 14:20-29.
20. Zhang L, et al (2002) Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol 161:2295-2309.
21. Roby KF, et al (2000) Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21:585-591.
22. Duraiswamy J, Freeman GJ, Coukos G. (2013) Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 73:6900-6912.
23. Lee Y, et al (2007) A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 211:26-35.
24. Singh N, et al (2016) Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide. Gynecol Oncol 141: 195-198.
25. Perets R, et al (2013) Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24: 751-765.
26. Sherman-Baust CA, et al (2014) A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol 233:228-237.
27. Walton J, et al (2016) CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma. Cancer Res 76: 6118-6129.
28. Hata K, Watanabe Y, Nakai H, Hata T, Hoshiai H. (2011) Expression of the vascular endothelial growth factor (VEGF) gene in epithelial ovarian cancer: An approach to anti-VEGF therapy. Anticancer Res 31:731-737.
29. Li Z, et al (2016) The inflammatory microenvironment in epithelial ovarian cancer: A role for TLR4 and MyD88 and related proteins. Tumour Biol 37:13279-13286.
30. Janát-Amsbury MM, Yockman JW, Anderson ML, Kieback DG, Kim S.W. (2006) Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer. Anticancer Res 26:2785-2789.
31. Baert T, et al (2015) The dark side of ID8-Luc2: Pitfalls for luciferase tagged murine models for ovarian cancer. J Immunother Cancer 3:57.
32. Peter S, Bak G, Hart K, Berwin B. (2009) Ovarian tumor-induced T cell suppression is alleviated by vascular leukocyte depletion. Transl Oncol 2:291-299.
33. Abiko K, et al (2013) PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 19: 1363-1374.
34. Wei H, et al (2013) Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One 8: e84927.
35. Ostrand-Rosenberg S, Sinha P. (2009) Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol 182:4499-4506.
36. Bingle L, Brown NJ, Lewis C.E. (2002) The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 196:254-265.
37. Shultz LD, Ishikawa F, Greiner D.L. (2007) Humanized mice in translational biomedical research. Nat Rev Immunol 7:118-130.
38. Tsai HC, et al (2012) Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21: 430-446.
39. Weller EM, Poot M, Hoehn H. (1993) Induction of replicative senescence by 5-azacytidine: Fundamental cell kinetic differences between human diploid fibroblasts and NIH-3T3 cells. Cell Prolif 26:45-54.
40. Alexander VM, Roy M, Steffens KA, Kunnimalaiyaan M, Chen H. (2010) Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids. Int J Clin Exp Med 3:95-102.
41. Liu M, et al (2016) Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine. Proc Natl Acad Sci USA 113:10238-10244.
42. Janát-Amsbury MM, Yockman JW, Anderson ML, Kieback DG, Kim S.W. (2006) Combination of local, non-viral IL12 gene therapy and systemic paclitaxel chemotherapy in a syngeneic ID8 mouse model for human ovarian cancer. Anticancer Res 26: 3223-3228.
43. West AC, et al (2013) An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. Cancer Res 73:7265-7276.
44. Leonova KI, et al (2013) p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc Natl Acad Sci USA 110:E89-E98.
45. Muller PA, Vousden K.H. (2013) p53 mutations in cancer. Nat Cell Biol 15:2-8.
46. Karpf AR, Moore BC, Ririe TO, Jones D.A. (2001) Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine. Mol Pharmacol 59:751-757.
47. Katlinski KV, et al (2017) Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell 31:194-207.
48. Gao J, et al (2016) Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167:397-404.e9.
49. Kang K, et al (2017) Interferon-γ represses M2 gene expression in human macrophages by disassembling enhancers bound by the transcription factor MAF. Immunity 47:235-250.e4.
50. Benci JL, et al (2016) Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167:1540-1554.e12.
51. Carr MW, Roth SJ, Luther E, Rose SS, Springer T.A. (1994) Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 91: 3652-3656.
52. Xu LL, Warren MK, Rose WL, Gong W, Wang J.M. (1996) Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J Leukoc Biol 60:365-371.
53. Dufour JH, et al (2002) IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168:3195-3204.
54. Au KK, et al (2017) CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer. Gynecol Oncol 145:436-445.
55. Fresco R, Glaspy J, Palodichuk C. (2016) Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation with CC-486 in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer, NCT02900560 (Natl Libr Med, Bethesda, MD). Clinicaltrials.gov.
56. Henke C, et al (2013) Regulation of murine placentogenesis by the retroviral genes syncytin-A, syncytin-B and Peg10. Differentiation 85:150-160.
57. Henke C, et al (2015) Selective expression of sense and antisense transcripts of the sushi-ichi-related retrotransposon-derived family during mouse placentogenesis. Retrovirology 12:9.
58. Mathios D, et al (2016) Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci Transl Med 8:370ra180.
59. Hirano F, et al (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65:1089-1096.
60. Swann JB, et al (2007) Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 178:7540-7549.
61. Hu J, Ge H, Newman M, Liu K. (2012) OSA: A fast and accurate alignment tool for RNA-seq. Bioinformatics 28:1933-1934.
62. Li B, Dewey C.N. (2011) RSEM: Accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics 12:323.
63. Law CW, Chen Y, Shi W, Smyth G.K. (2014) voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 15:R29.
64. Ross SM (2003) Peirce's criterion for the elimination of suspect experimental data. J Eng Technol 20:38-41.
65. Munclinger P, Boursot P, Dod B. (2003) B1 insertions as easy markers for mouse population studies. Mamm Genome 14:359-366.